Mercer Global Advisors
CMPX icon

Mercer Global Advisors’s Compass Therapeutics CMPX Stock Holding History

Mercer Global Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$233K Buy
+106,570
New +$315K ﹤0.01% 3086

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Mercer Global Advisors's CMPX Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Compass Therapeutics (CMPX) in Q2 2026: 106,570 shares worth $233K. The stake represents ﹤0.01% of the portfolio and ranks #3086 among its holdings.

215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Mercer Global Advisors held 106,570 shares of Compass Therapeutics worth $233K as of Q2 2026.
  • Compass Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • Compass Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3086 holding.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.